IXICO PLC has updated investors on the Huntington's Disease Imaging Harmonization Consortium (HD-IH) consortium which is working on technologies to better understand the structural brain changes that occur over the course of the disease.
The AI and data analytics specialist highlighted that the consortium, previously announced in May 2022, will use artificial intelligence technology to conduct large-scale analysis of brain changes in Huntington's disease
The consortium will analyse over 6,000 sets of magnetic resonance images (MRI) from over 2,000 participants. It aims to systematically conduct harmonized analysis across three study cohorts to produce a rich dataset.
"Harmonized analysis across heterogeneous data is a critical requirement to enable more targeted clinical trial design through the inclusion of novel biomarkers,” said Robin Wolz, IXICO chief scientific officer in a statement.
“We're excited to support this important project in our endeavour to bring novel imaging biomarkers into clinical trials," he added.
The current phase of work is scheduled to complete by the end of 2022.